INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY;한양대학교 산학협력단
发明人:
KIM, Chul Geun,김철근,LEE, Sang Won,이상원,JEONG, Jae Min,정재민,CHOI, Dong Ho,최동호,JANG, Ki Seok,장기석,KIM, Min Young,김민영,KIM, Chan Gil,김찬길,SON, Seung Han,손승환,KIM, Ji Sook,김지숙,CHOI, Sung Woo,최성우,LEE, Seol Eui,이설
申请号：
KRKR2020/004467
公开号：
WO2020/204605A1
申请日:
2020.04.01
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
The present invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the present invention binds to transcription factor CP2c so as to inhibit the formation of transcription factor complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer) comprising CP2c, thereby inducing cancer cell-specific cell death, and binds a fatty acid to the peptide so as to ensure stability enabling long-term sustenance in vivo.La présente invention concerne un agent anticancéreux à base de peptide ciblant CP2c. Un peptide ciblant CP2c selon la présente invention se lie au facteur de transcription CP2c de manière à inhiber la formation de complexes de facteurs de transcription (homotétramère CP2c et hétérohexamère CP2c/CP2b/PIAS1) comprenant CP2c, ce qui induit la mort cellulaire spécifique des cellules cancéreuses, et lie un acide gras au peptide de manière à assurer une stabilité permettant une conservation à long terme in vivo.본 발명은 CP2c 표적 펩티드 기반 항암제에 관한 것이다. 본 발명에 따른 CP2c 표적 펩티드는 전사인자 CP2c에 결합하여 CP2c를 포함하는 전사인자 복합체 (CP2c homotetramer 및 CP2c/CP2b/PIAS1 heterohexamer) 형성을 억제함으로써 암세포 특이적 세포사를 유도하는 펩티드로, 이와 같은 펩티드에 지방산을 결합시킴으로써 생체 내에서 장기간 지속될 수 있는 안정성을 확보할 수 있다.
